S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa

Moderna Stock Price, News & Analysis (NASDAQ:MRNA)

$80.32
+0.37 (+0.46%)
(As of 12/8/2023 ET)
Compare
Today's Range
$78.76
▼
$81.82
50-Day Range
$69.51
▼
$104.43
52-Week Range
$62.55
▼
$217.25
Volume
2.93 million shs
Average Volume
3.03 million shs
Market Capitalization
$30.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$133.70
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Moderna MarketRank™ Stock Analysis

Analyst Rating
Hold
2.15 Rating Score
Upside/​Downside
66.5% Upside
$133.70 Price Target
Short Interest
Bearish
6.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.71
Upright™ Environmental Score
News Sentiment
0.39mentions of Moderna in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$10.86 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($5.97) to ($6.69) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

230th out of 932 stocks

Biological Products, Except Diagnostic Industry

39th out of 160 stocks

See Top Rated MarketRank™ Stocks Here

MRNA stock logo

About Moderna Stock (NASDAQ:MRNA)

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. 

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. 

MRNA Stock Price History

MRNA Stock News Headlines

November 28, 2023 | marketbeat.com
Upwork underscores the strength of the AI gig economy (MRNA)
Upwork has been pursuing its goal of being the world's preeminent destination for artificial intelligence (AI) related talent and freelancers
December 8, 2023 | msn.com
Researchers discover new lipid nanoparticle that shows muscle-specific mRNA delivery, reduces off-target effects.
December 10, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
December 8, 2023 | finance.yahoo.com
Moderna, Inc.: Moderna's mRNA Technology Is Supporting a Broad Pipeline Beyond COVID-19
December 8, 2023 | benzinga.com
Moderna's Options Frenzy: What You Need to Know
December 7, 2023 | seekingalpha.com
Moderna, Inc. (MRNA) 2023 ESG Day Conference (Transcript)
December 7, 2023 | finanznachrichten.de
Moderna, Inc.: Moderna Reviews its Environmental, Social and Governance Progress and Ambitions at Second ESG Investor Event
December 6, 2023 | msn.com
Covid study: mRNA vaccines could be fine-tuned
December 10, 2023 | Wealthpress (Ad)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
December 6, 2023 | msn.com
More than one in four who had mRNA Covid jabs experienced unintended immune response, survey finds
December 4, 2023 | americanbankingnews.com
JPMorgan Chase & Co. Trims Moderna (NASDAQ:MRNA) Target Price to $90.00
December 4, 2023 | americanbankingnews.com
Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of "Hold" by Brokerages
December 3, 2023 | americanbankingnews.com
Moderna (NASDAQ:MRNA) Trading Down 3.5% After Analyst Downgrade
December 1, 2023 | markets.businessinsider.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CytomX Therapeutics (CTMX), BiomX (PHGE) and Moderna (MRNA)
December 1, 2023 | benzinga.com
Global mRNA Platform Market Research Report 2023-2028: Post COVID-19 Vaccines, mRNA's Promise in Cancer Immunotherapy and Personalized Medicine
December 1, 2023 | americanbankingnews.com
Moderna (NASDAQ:MRNA) Coverage Initiated at Canaccord Genuity Group
November 30, 2023 | seekingalpha.com
Moderna, Inc. (MRNA) Presents at 35th Annual Piper Sandler Healthcare Conference (Transcript)
November 30, 2023 | finance.yahoo.com
Moderna, Inc.'s (NASDAQ:MRNA) Intrinsic Value Is Potentially 92% Above Its Share Price
November 30, 2023 | americanbankingnews.com
Moderna (NASDAQ:MRNA) Earns Hold Rating from Analysts at Canaccord Genuity Group
November 29, 2023 | msn.com
Canaccord Genuity Initiates Coverage of Moderna (MRNA) with Hold Recommendation
November 29, 2023 | msn.com
Canaccord starts Moderna at hold, says valuation properly reflects risk/reward
November 29, 2023 | ca.investing.com
Moderna valuation reflects current risk/reward despite 'significant opportunity'
November 29, 2023 | markets.businessinsider.com
Analyst Expectations for Moderna's Future
November 28, 2023 | realmoney.thestreet.com
Moderna initiated with a Hold at Canaccord
November 28, 2023 | msn.com
Moderna starts building mRNA plant in China
November 27, 2023 | msn.com
Moderna keeps tabs on ‘high risk’ anti-vaccine celebs like Elon Musk, Novak Djokovic, Russell Brand: report
November 22, 2023 | msn.com
CORRECTED-UPDATE 1-European Patent Office declares Moderna mRNA patent invalid
See More Headlines
Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRNA
CUSIP
N/A
CIK
1682852
Web
www.modernatx.com
Phone
(617) 714-6500
Fax
N/A
Employees
3,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$133.70
High Stock Price Target
$231.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+66.5%
Consensus Rating
Hold
Rating Score (0-4)
2.15
Research Coverage
20 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($9.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$8.36 billion
Net Margins
-38.00%
Pretax Margin
-25.84%
Return on Equity
-2.14%
Return on Assets
-1.60%

Debt

Debt-to-Equity Ratio
0.04
Current Ratio
2.46
Quick Ratio
2.35

Sales & Book Value

Annual Sales
$19.26 billion
Price / Sales
1.59
Cash Flow
$22.88 per share
Price / Cash Flow
3.51
Book Value
$49.78 per share
Price / Book
1.61

Miscellaneous

Outstanding Shares
381,280,000
Free Float
321,422,000
Market Cap
$30.62 billion
Optionable
Optionable
Beta
1.62

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Moderna was last updated on Tuesday, November 28, 2023 at 1:23 PM.

Pros

Here are some ways that investors could benefit from investing in Moderna, Inc.:

  • Moderna, Inc. is a biotechnology company that discovers, develops, and commercializes messenger RNA therapeutics and vaccines for various diseases, including infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases.
  • Moderna has developed respiratory vaccines, including COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines, which have gained significant attention and demand in recent times.
  • The company also offers latent vaccines for cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus, addressing a wide range of diseases.
  • Moderna has strategic alliances and collaborations with reputable organizations such as AstraZeneca, Merck, and The Bill & Melinda Gates Foundation, which provide opportunities for research, development, and market expansion.
  • Recent insider selling activity indicates confidence in the company's stock, with corporate insiders owning a significant portion of the company's stock.

Cons

Investors should be bearish about investing in Moderna, Inc. for these reasons:

  • Investing in biotechnology companies carries inherent risks, including regulatory challenges, clinical trial failures, and competition from other companies in the industry.
  • The stock price of Moderna, Inc. has experienced significant volatility in recent periods, which may deter some investors who prefer more stable investments.
  • While Moderna has achieved success with its COVID-19 vaccine, the long-term sustainability of its business model and the ability to maintain a competitive edge in the rapidly evolving biotechnology industry remain uncertain.
  • The company's financial performance and revenue generation may be influenced by factors such as patent expirations, market demand fluctuations, and changes in healthcare policies.
  • Investors should carefully consider their risk tolerance and conduct thorough research before making investment decisions in Moderna, Inc. or any biotechnology company.














MRNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Moderna stock right now?

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last twelve months. There are currently 3 sell ratings, 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings or view top-rated stocks.

What is Moderna's stock price target for 2024?

20 brokerages have issued 12 month price targets for Moderna's shares. Their MRNA share price targets range from $60.00 to $231.00. On average, they predict the company's share price to reach $133.70 in the next twelve months. This suggests a possible upside of 66.5% from the stock's current price.
View analysts price targets for MRNA or view top-rated stocks among Wall Street analysts.

How have MRNA shares performed in 2023?

Moderna's stock was trading at $179.62 at the beginning of 2023. Since then, MRNA stock has decreased by 55.3% and is now trading at $80.32.
View the best growth stocks for 2023 here.

When is Moderna's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our MRNA earnings forecast.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) announced its earnings results on Thursday, November, 2nd. The company reported ($1.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.01) by $0.62. The company had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $1.37 billion. Moderna had a negative net margin of 38.00% and a negative trailing twelve-month return on equity of 2.14%.

What ETFs hold Moderna's stock?

ETFs with the largest weight of Moderna (NASDAQ:MRNA) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), iShares Genomics Immunology and Healthcare ETF (IDNA), ProShares Nanotechnology ETF (TINY) and iShares U.S. Tech Breakthrough Multisector ETF (TECB).

What is Stéphane Bancel's approval rating as Moderna's CEO?

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

When did Moderna IPO?

(MRNA) raised $499 million in an initial public offering on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Who are Moderna's major shareholders?

Moderna's stock is owned by a number of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.97%), Wellington Management Group LLP (1.47%), Morgan Stanley (1.39%), The Manufacturers Life Insurance Company (1.02%), FMR LLC (1.01%) and Banque Pictet & Cie SA (0.82%). Insiders that own company stock include Arpa Garay, David W Meline, Dustin A Moskovitz, James M Mock, Juan Andres, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and W Don Cornwell.
View institutional ownership trends.

How do I buy shares of Moderna?

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MRNA) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -